STAT3在肿瘤免疫应答中的作用机制研究进展

doi:10.3969/j.issn.1006-7795.2025.03.007

首都医科大学学报 ›› 2025, Vol. 46 ›› Issue (3): 442-447.doi: 10.3969/j.issn.1006-7795.2025.03.007

• 肿瘤研究进展：从基础到临床 • 上一篇下一篇

STAT3在肿瘤免疫应答中的作用机制研究进展

张文秀^1,2,3,4,熊阳^1,2,3,4,于明航^1,2,3,4*#,王玺^1,2,3,4*#

1.传染病溯源预警与智能决策全国重点实验室，首都医科大学附属北京地坛医院，北京 100015；2.首都医科大学附属北京地坛医院传染病研究所，新发突发传染病研究北京市重点实验室，首都医科大学附属北京地坛医院国家传染病医学中心，北京 100015；3.北京市感染性疾病研究中心，北京 100015；4.首都医科大学肿瘤学系，北京 100069

收稿日期:2025-02-27 出版日期:2025-06-21 发布日期:2025-06-25
通讯作者: 于明航,王玺 E-mail:xiwang@ccmu.edu.cn；yumhang@ccmu.edu.cn
基金资助:
国家自然科学基金项目（32270635），北京市自然科学基金项目（7232082, 5254029），首都医科大学附属北京地坛医院院内科研基金（DTQL-202405）。

Advances in the role of STAT3 in tumor immunology

Zhang Wenxiu^1,2,3,4, Xiong Yang^1,2,3,4, Yu Minghang^1,2,3,4*#, Wang Xi^1,2,3,4*#

1.National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University Beijing 100015, China; 2.Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China; 3.Beijing Institute of Infectious Diseases, Beijing 100015, China; 4.Department of Oncology, Capital Medical University, Beijing 100069, China

Received:2025-02-27 Online:2025-06-21 Published:2025-06-25
Supported by:
This study was supported by National Natural Science Foundation of China（32270635）, Natural Science Foundation of Beijing（7232082, 5254029），Science Fundation of Beijing Ditan Hospital, Capital Medical University (DTQL-202405).

摘要/Abstract

摘要： 信号转导和转录激活因子3（signal transducer and activator of transcription 3, STAT3）是一种核转录因子，其功能除调节细胞周期、细胞存活相关基因的表达之外，还参与肿瘤相关免疫应答反应。STAT3活化可以驱动肿瘤细胞增殖，抵抗细胞凋亡，促进肿瘤的血管生成和转移等，且STAT3的异常激活与肿瘤预后不良相关。STAT3是介导肿瘤免疫逃逸的主要驱动因素之一，因此其成为免疫治疗中有效靶点之一。本文将从STAT3在固有免疫、适应性免疫及肿瘤免疫中的作用等几个方面进行阐述，并展望未来亟待解决的问题及进一步的研究方向。

关键词: 信号转导, STAT3, 免疫, 肿瘤免疫, 免疫治疗

Abstract: Signal transducer and activator of transcription 3 (STAT3) are nuclear transcription factors that regulates expression of genes that are involved in cell cycle, cell survival, and cancer-related immune response. Activated STAT3 may participate in oncogenesis by stimulating cell proliferation, resisting apoptosis and promoting tumor angiogenesis and metastasis. Furthermore, abnormal activation of STAT3 is associated with poor tumor prognosis. Recent advances have revealed a crucial role of persistent activation of STAT3 in cancer progression and immune escape. STAT3 is also an important driver of mediated immune escape in tumor immunity, so it has become an effective target in immunotherapy. Therefore, STAT3 became frequently studied targets for more specific cancer immunotherapies. This article elaborated the multiple functions of STAT3 in innate immunity, adaptive immunity and tumor immunity. Further, it put forward to the prospects and issues that urgently need to be addressed in the future.

Key words: signal transducer and activator of transcription, STAT3, immunology, tumor immunology, immunotherapy

中图分类号:

R392.9

张文秀, 熊阳, 于明航, 王玺. STAT3在肿瘤免疫应答中的作用机制研究进展[J]. 首都医科大学学报, 2025, 46(3): 442-447.

Zhang Wenxiu, Xiong Yang, Yu Minghang, Wang Xi. Advances in the role of STAT3 in tumor immunology[J]. Journal of Capital Medical University, 2025, 46(3): 442-447.

参考文献

［1］Witalisz-Siepracka A, Klein K, Zdársky B, et al. The multifaceted role of STAT3 in NK-Cell tumor surveillance［J］. Front Immunol, 2022, 13: 947568.
［2］Ma J H, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer［J］. Cell Commun Signal, 2020, 18(1): 33.
［3］Zou S L, Tong Q Y, Liu B W, et al. Targeting STAT3 in cancer immunotherapy［J］. Mol Cancer, 2020, 19(1): 145.
［4］Jin W. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition［J］. Cells, 2020, 9(1): 217.
［5］Amaya M L, Inguva A, Pei S S, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation［J］. Blood, 2022, 139(4): 584－596.
［6］Tošic′ I, Frank D A. STAT3 as a mediator of oncogenic cellular metabolism: pathogenic and therapeutic implications［J］. Neoplasia, 2021, 23(12): 1167－1178.
［7］Huynh J, Chand A, Gough D, et al. Therapeutically exploiting STAT3 activity in cancer － using tissue repair as a road map［J］. Nat Rev Cancer, 2019, 19(2): 82－96.
［8］Xu J N, Lin H F, Wu G, et al. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma［J］. Front Oncol, 2021, 11: 760971.
［9］Wang X, Wang J, Zhao J H, et al. HMGA2 facilitates colorectal cancer progression via STAT3-mediated tumor-associated macrophage recruitment［J］. Theranostics, 2022, 12(2): 963－975.
［10］Liu C, Yao Z Y, Wang J N, et al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway［J］. Cell Death Differ, 2020, 27(6): 1765－1781.
［11］Kim S Y, Park S, Kim S, et al. CD133-containing microvesicles promote cancer progression by inducing M2-like tumor-associated macrophage polarization in the tumor microenvironment of colorectal cancer［J］. Carcinogenesis, 2024, 45(5): 300－310.
［12］Shi X, Chen W, Yin Y, et al. RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis［J］. Cancer Lett, 2024, 592: 216909.
［13］Gotthardt D, Putz E M, Straka E, et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance［J］. Blood, 2014, 124(15): 2370－2379.
［14］Neo S Y, Tong L, Chong J, et al. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis［J］. Sci Transl Med, 2024, 16(747): eadi2952.
［15］Chou W C, Levy D E, Lee C K. STAT3 positively regulates an early step in B-cell development［J］. Blood, 2006, 108(9): 3005－3011.
［16］Xiao S X, Fan C B, Ma J L, et al. STAT3 promotes cell proliferation by potentiating the CCL4 transcriptional activity in diffuse large B-Cell lymphoma［J］. Acta Haematol, 2022, 145(4): 371－383.
［17］Hu S F, Ren S, Cai Y Q, et al. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of wnt－β-catenin-STAT3 signaling［J］. Cell Death Differ, 2022, 29(3): 642－656.
［18］Gao Y M, Ding X J. miR-145－5p exerts anti-tumor effects in diffuse large b-cell lymphoma by regulating S1PR1/STAT3/AKT pathway［J］. Leuk Lymphoma, 2021, 62(8): 1884－1891.
［19］Wang L, Zhou M, Kong X, et al. Specific targeting of STAT3 in B cells suppresses progression of B cell lymphoma［J］. Int J Mol Sci, 2023, 24(17): 13666.
［20］Dong C. Cytokine regulation and function in T cells［J］. Annu Rev Immunol, 2021, 39: 51－76.
［21］Chen X, Ma C N, Li Y M, et al. Trim21-mediated CCT2 ubiquitination suppresses malignant progression and promotes CD4+T cell activation in breast cancer［J］. Cell Death Dis, 2024, 15(7): 542.
［22］Hanna B S, Llaó-Cid L, Iskar M, et al. Interleukin－10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity［J］. Immunity, 2021, 54(12): 2825－2841.e10.
［23］Zhang C Y, Yue C Y, Herrmann A, et al. STAT3 Activation-Induced fatty acid oxidation in CD8+ T effector cells is critical for obesity-promoted breast tumor growth［J］. Cell Metab, 2020, 31(1): 148－161.e5.
［24］Sun Q, Zhao X, Li R, et al. STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection［J］. J Exp Med, 2023, 220(4): e20220686.
［25］Ishteyaque S, Singh G, Yadav K S, et al. Cooperative STAT3-NFkB signaling modulates mitochondrial dysfunction and metabolic profiling in hepatocellular carcinoma［J］. Metabolism, 2024, 152: 155771.
［26］Cao T Y, Zhang W Y, Wang Q, et al. Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells［J］. Cell, 2024, 187(9): 2288－2304.e27.
［27］Xu W L, Li S L, Li M, et al. Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma［J］. Immunol Lett, 2021, 240: 31－40.
［28］Oweida A J, Darragh L, Phan A, et al. STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck cancer［J］. J Natl Cancer Inst, 2019, 111(12): 1339－1349.
［29］Manoharan S, Perumal E. A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: advances and insights［J］. Fitoterapia, 2024, 179: 106265.
［30］Jonker D J, Nott L, Yoshino T, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial［J］. Lancet Gastroenterol Hepatol, 2018, 3(4): 263－270.
［31］Hong D, Kurzrock R, Kim Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer［J］. Sci Transl Med, 2015, 7(314): 314ra185.
［32］Odate S, Veschi V, Yan S, et al. Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity［J］. Clin Cancer Res, 2017, 23(7): 1771－1784.
［33］Yoyen-Ermis D, Tunali G, Tavukcuoglu E, et al. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS［J］. Sci Rep, 2019, 9(1): 11697.
［34］Chiba M, Shimono J, Suto K, et al. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma［J］. Blood, 2024, 143(14): 1379－1390.
［35］Brudno J N, Maus M V, Hinrichs C S. CAR T cells and T-cell therapies for cancer: a translational science review［J］. JAMA, 2024, 332(22): 1924－1935.
［36］Kagoya Y, Tanaka S, Guo T X, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects［J］. Nat Med, 2018, 24(3): 352－359.

[1]	汪婧雯, 李振军, 吕亮成, 姚晓雨, 丁宁. B细胞受体信号通路在B细胞淋巴瘤中的作用及靶向治疗策略[J]. 首都医科大学学报, 2025, 46(3): 436-441.
[2]	李铁铮, 胥凯凯, 邓钰卿, 王沛豪, 秦齐, 郭康顺, 王炳仁, 常栋, 崔永. PD-1单抗联合化学药物治疗在局部晚期非小细胞肺癌新辅助治疗中的疗效和安全性分析[J]. 首都医科大学学报, 2024, 45(4): 636-641.
[3]	王居巳, 宋伟安, 狄守印, 刘军强, 范博士, 周少华, 岳彩迎, 赵嘉华, 陈思禹, 龚太乾. 新辅助化疗联合免疫抑制剂对Ⅲ期非小细胞肺癌治疗有效性分析[J]. 首都医科大学学报, 2024, 45(4): 660-665.
[4]	郝卓鸿, 云铎, 张颖, 李卉惠, 林海珊, 崔永, 赵磊. 非小细胞肺癌围手术期免疫治疗研究进展———新辅助免疫治疗进展[J]. 首都医科大学学报, 2024, 45(4): 666-677.

STAT3在肿瘤免疫应答中的作用机制研究进展

Advances in the role of STAT3 in tumor immunology

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价